Mannitol Dosage for Intracranial Hemorrhage
For treating intracranial hemorrhage with increased intracranial pressure or signs of brain herniation, administer mannitol 20% at a dose of 250 mOsm (approximately 0.25-1 g/kg) infused over 15-20 minutes, with larger doses up to 0.5-1 g/kg over 15 minutes appropriate for acute intracranial hypertensive crisis. 1
Recommended Dosing Protocol
Adults
- Standard dose: 0.25-1 g/kg of 20% mannitol IV over 20-30 minutes 2, 3
- Acute crisis: 0.5-1 g/kg over 15 minutes for acute intracranial hypertensive emergency 1
- Alternative dosing: 0.25-2 g/kg as 15-25% solution over 30-60 minutes 3
Pediatric Patients
- Standard dose: 1-2 g/kg or 30-60 g/m² body surface area over 30-60 minutes 2, 3
- Small/debilitated patients: 500 mg/kg may be sufficient 3
Critical Implementation Details
The 2018 French Society of Anaesthesia guidelines provide the strongest recommendation (Grade 1+) for using mannitol 20% or hypertonic saline at 250 mOsm over 15-20 minutes specifically for threatened intracranial hypertension or brain herniation signs after controlling secondary brain insults 1. This represents the most recent high-quality guideline evidence directly addressing your question.
Timing and Frequency
- Onset of action: Maximum ICP reduction occurs 10-15 minutes after infusion 1
- Duration of effect: 2-4 hours 1
- Repeat dosing: Can be administered every 4-6 hours as needed 4
- Research suggests every 4-hour dosing shows better ICP reduction in the first 4 days compared to longer intervals 4, though guideline recommendations favor the 250 mOsm dose approach
Essential Monitoring Requirements
Place a urinary catheter before mannitol administration 2. Monitor:
- Serum osmolality every 6 hours - hold if ≥320 mOsm/kg 5, 3
- Fluid and electrolyte balance (sodium, chloride) 1
- Renal function 3
- Cardiovascular status 3
Administration Precautions
Administer through a filter; do not use solutions containing crystals 2. The FDA label emphasizes inspecting for particulate matter and avoiding PVC bags with 25% mannitol due to precipitation risk 3.
Comparative Efficacy
At equiosmotic doses (~250 mOsm), mannitol and hypertonic saline have comparable efficacy for treating intracranial hypertension 1. However, mannitol was the only therapy among ICP-lowering treatments (including external ventricular drainage and hyperventilation) associated with improved cerebral oxygenation 1.
Side Effect Profile
- Mannitol: Osmotic diuresis requiring volume compensation 1
- Hypertonic saline: Hypernatremia and hyperchloremia risk 1
Evidence Regarding Prophylactic Use
Important caveat: The 2022 AHA/ASA guidelines note that prophylactic hypertonic saline in patients without evidence of intracranial hypertension was not superior to crystalloids 6. Recent research (2026) suggests prophylactic prolonged mannitol administration may be associated with increased perihemorrhagic edema and poor outcomes 7, though short-term use up to 72 hours may still have benefit.
Use mannitol for treatment of documented or clinically evident increased ICP, not prophylactically 1, 6.
Multimodal Approach
Mannitol should be used alongside other ICP management measures 2:
- Head-of-bed elevation to 30 degrees 5
- Sedation/analgesia
- Cerebrospinal fluid drainage if available
- Avoid prolonged hyperventilation (target PaCO₂ 30-40 mmHg only acutely) 1
- Consider barbiturates or neuromuscular blockade for refractory cases
Contraindications
Do not administer mannitol if 3:
- Well-established anuria from severe renal disease
- Severe pulmonary congestion or frank pulmonary edema
- Active intracranial bleeding (except during craniotomy)
- Severe dehydration
- Progressive heart failure after mannitol initiation
- Known hypersensitivity to mannitol
Dose-Response Considerations
Research demonstrates the ICP-lowering effect of mannitol is dose-dependent during the reduction phase but not after reaching stable ICP 4, 8. Smaller doses (0.25 g/kg) can be as effective as larger doses (1 g/kg) for acute ICP reduction 9, supporting the guideline recommendation of starting with lower doses and titrating based on response rather than routinely using maximum doses.